Anifrolumab (Saphnelo®, Astra Zeneca AB), is a humanized IgG1k monoclonal antibody therapy that binds to a subunit of the IFN-I receptor (IFNAR1) and was recently approved to treat adult patients with Systemic Lupus Erythematosus (SLE) [9, 17, 18, 19, 20]. The gene discussed is IFNAR1; the disease is systemic lupus erythematosus.